Patient Assistance Program Application - JJPAF
(daratumumab) Injection for intravenous infusion. DARZALEX . FASPRO ® (daratumumab and hyaluronidase-fihj), Injection for ... treatment, care management, health insurance and benefits, medication history, and prescriptions (collectively, “Health Information”), whether in written or verbal form, including portions of my medical record. ...
Download Patient Assistance Program Application - JJPAF
Information
Domain:
Source:
Link to this page:
Documents from same domain
Patient Assistance Program Application - jjpaf.org
jjpaf.orgohnson ohnson Patient Assistance Foundation Inc. The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, non …
Related documents
Hypersensitivity & Infusion Reaction Management
intranet.stephensoncancercenter.orgFeb 21, 2019 · These is common with taxanes, rituximab, bleomycin, daratumumab, PEGylated liposomal doxorubicin and daunorubicin, trastuzumab, immunotherapy (list), brentuximab, ofatumumab, panitumumab. Related to the administration of the chemotherapy, the agent may or may not have an allergic ... Concomitant medication
Procedures, programs, and drugs that require precertification
member.aetna.comdrugs: 638 Other drugs and medical injectables For the following services, providers call 1-866-752-7021 or fax applicable request forms to 1-888-267-3277,
Procedures, programs and drugs that require …
www.aetna.com(daratumumab and hyaluronidase-fihj) Dupixent* (dupilumab) Empliciti (elotuzumab) Enzyme replacement drugs: Aldurazyme (laronidase) —precertification for the drug and site of care required Brineura (cerliponase alfa) Cerezyme (imiglucerase) —precertification for the drug and site of care required. Elaprase (idursulfase) — precertification
Blue Cross and BCN utilization management medical drug …
www.bcbsm.comThese pr ograms help ensure that patients receive medication that is medically necessary and appropriate for their situations. For most medical benefit drugs . Submit prior authorization requests through the . ... daratumumab-hyaluronidase-fihj . PPO .
Daratumumab, bortezomib & dexamethasone (DVd)
www.swagcanceralliance.nhs.ukSubcutaneous daratumumab Administer via sub-cutaneous injection over 5 minutes. Patients should be observed for at least 6 hours after the end of the SC injection following the first dose (or as per local policy) and, if deemed necessary, after subsequent injections. Pre-medication 1-3 hours prior to daratumumab infusion (or subcutaneous ...